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Bromelain, a widely used pineapple extract with cysteine protease activity, has been shown to
have immunomodulatory effects in a variety of immune system models. The purpose of the
present study was to determine the effects of orally administered bromelain in an ovalbumin
(OVA)-induced murine model of acute allergic airway disease (AAD). To establish AAD,
female C57BL/6J mice were sensitized with intraperitoneal (i.p.) OVA/alum and then
challenged with OVA aerosols for 3 days. Mice were gavaged with either (phosphate buffered
saline)PBS or 200mg/kg bromelain in PBS, twice daily for four consecutive days, beginning
1day prior to OVA aerosol challenge. Airway reactivity and methacholine sensitivity,
bronchoalveolar lavage (BAL) cellular differential, Th2 cytokines IL-5 and IL-13, and lung
histology were compared between treatment groups. Oral bromelain-treatment of AAD mice
demonstrated therapeutic efficacy as evidenced by decreased methacholine sensitivity (P 0.01),
reduction in BAL eosinophils (P 0.02) and IL-13 concentrations (P 0.04) as compared with
PBS controls. In addition, oral bromelain significantly reduced BAL CD19þ B cells
(P 0.0001) and CD8þ T cells (P 0.0001) in AAD mice when compared with controls.
These results suggest that oral treatment with bromelain had a beneficial therapeutic effect in
this murine model of asthma and bromelain may also be effective in human conditions.
Keywords: airway inflammation – asthma – CD19þ B Cells – CD8þ T Cells – cysteine
protease – eosinophils – IL-13 – immuno-modulation
Introduction
The prevalence and severity of asthma continues to
increase despite new pharmacological advances for both
acute treatment and chronic disease management. The
benefits of lifestyle changes and alternative asthma
treatments are being investigated in the hope that safe
and efficacious adjunctive therapies will be added to
current treatment formulary (1–8). According to the
National Institutes of Health, over 60% of Americans use
complementary and alternative medicine with  20%
using natural products or specific botanical formula-
tions to supplement their health care needs (9). Botanicals
such as Boswellia serrata, Petasites hybridus, Astragalus
membranaceus, Echinacea angustifolia and Ananas
comosus (common pineapple) and specific extracts such
as bromelain from pineapple are being investigated as
therapeutic agents in inflammatory conditions such as
ulcerative colitis, multiple sclerosis and asthma (10–17).
Bromelain is a commonly used botanical extract, and is
normally delivered as a powder either encapsulated in
gelatin or prepared in an enteric coated tablet. Bromelain
is available in combination with other natural products
such as in Phlogenzym (Bromelain, trypsin and rutosid
trihydrate), Wobenzym (Bromelain, trypsin, rutosid
trihydrate, pancreatin, papain and phymotrypsin)
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Bromelain (enzyme classification 3.4.22.32) is a combina-
tion of sulfur-containing cysteine endopeptidases that
have a broad specificity for the cleavage of proteins. One
mechanism of action proposed to account for bromelain’s
therapeutic activity is the cleavage of lymphocyte cell
surface receptors such as CD4, CD8, CD44 and CD62L.
Receptor cleavage can result in altered cell communica-
tion, cell trafficking and cell signaling pathways leading
to the modulation of pro- and anti-inflammatory
cytokines such as IL-2, IL-4, IL-6 and TNF-a (18–22).
Experimental animal models, such as the ovalbumin
(OVA)-induced model of allergic airway disease (AAD),
are utilized to investigate the underlying mechanisms and
potential therapies for asthma. Asthma is complex with
characteristic airway hyperresponsiveness, airway inflam-
mation, increased mucus and airway remodeling; measur-
able outcomes are produced similar to those found in
humans. These outcomes include increases in inflamma-
tory Th2 cytokines (IL-4, IL-5, IL-6 and IL-13),
enhanced airway hyperresponsiveness, and increased
total white blood cells, eosinophils and CD4þ T
lymphocytes recovered from the bronchoalveolar lavage
(BAL) (23–25).
The effect of intraperitoneally (i.p.) injected bromelain
has been previously characterized in an OVA-induced
murine model AAD (23). Bromelain treatment was found
to be well-tolerated and non-toxic in both naive and
AAD mice. Bromelain significantly reduced total BAL
leukocytes, eosinophils and CD4þ T cells and lowered
the concentration of IL-13 in the BAL. In order to better
mimic the clinical environment and consider the effects
of digestion and degradation on enzymatic activity,
the oral administration of bromelain was adapted in
this AAD model. The present study was designed
to determine whether oral bromelain treatment had
an anti-inflammatory or immunoregulatory effect in an
OVA-induced murine model of acute AAD.
Methods
Mice
Female C57BL/6J mice, 3–6 months of age and weighing
17–24g, were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA), and housed conventionally in
plastic cages with corncob bedding. The mouse room was
maintained at 22–24 C with a daily light/dark cycle (light
from 0600 to 1800h). Chow and water were supplied ad
libitum. Seven to eight mice were used per group. The
protocols for mice used were approved by the Animal
Care Committee at the University of Connecticut Health
Center.
Ovalbumin Sensitization and Aerosol Exposure Protocol
Mice were immunized with three weekly i.p. injections of
a suspension containing 25mg of OVA (grade V, Sigma
Chemical Co., St. Louis, MO, USA) and 2mg of
aluminum hydroxide (alum) in 0.5ml of 0.9% sodium
chloride (pH 5.5, 308mOsmolL
 1; Baxter Healthcare
Corporation, Deerfield, IL, USA). One week after the
last injection the mice were exposed to 1% aerosolized
OVA in sodium chloride, 1h per day, for 3 days (acute
AAD model) (23,24). The mice were placed in plastic
restraint tubes (Research and Consulting Co., Basel,
Switzerland) for nose-only aerosol exposure. The aerosols
were generated by a BANG nebulizer (CH Technologies,
Westwood, NJ, USA) into a 7.6l inhalation exposure
chamber to which restraint tubes were attached. Chamber
airflow was 6lmin
 1, and aerosol particle size of OVA
was monitored by gravimetric analysis with a Mercer
cascade impactor (In-Tox Products, Moriarty, NM,
USA). The mass median aerodynamic diameter and
geometric standard deviations were 1.4 and 1.6mm,
respectively. The estimated daily inhaled OVA dose
 30–40mg per mouse. Twenty-four hours after the final
aerosol exposure, the mice were sacrificed by overdose
(0.15ml i.p. injection per 20g mouse of: 13mg Ketamine
HCL, Ketaset-III
TM Fort Dodge Animal Health, Fort
Dodge IA, USA, and 0.4mg of xylazine, Tranquived
TM
Vedco, St Joseph, MO, USA) and exsanguination.
Airway Hyperresponsiveness
Airway responses to methacholine were assessed by whole-
body barometric plethysmography, using the Buxco system
(Buxco Electronics, Troy, NY, USA), as previously
described (23). Briefly, mice were evaluated for maximal
enhanced pause (Penh), 24h before treatment and 12h
after the third OVA aerosol was administered. Mice were
placed in individual chambers and exposed for 2min
to aerosolized saline or increasing concentrations of
methacholine from 3 to 300mgml
 1. Respiratory system
variables including tidal volume, respiratory frequency,
inspiratory and expiratory times and changes in box
pressure were recorded before and during aerosolization
and for 4min after each exposure. The Penh value response
to methacholine was recorded at each dose. The entire
dose–response relationship to methacholine was compared
in individual animals before and after OVA aerosol
exposures. In addition, individual animal sensitivity to
methacholine was measured by the interpolated concentra-
tion of methacholine needed to increase the Penh value to
two units (the ‘Penh-2’ value). The Penh-2 value was
selected as the portion of the dose–response curve in which
the greatest changes in sensitivity would be manifested (25).
Increased sensitivity to methacholine during AAD was
demonstrated by a decreased Penh-2 value (i.e. less
methacholine needed to elicit the response).
62 Oral bromelain: effects in murine asthmaBAL Fluid Analysis
At time of sacrifice the lungs were lavaged in situ with five
1ml aliquots of sodium chloride. The BAL fluid was
centrifuged at 200g for 10min, the cellular pellet was
resuspended in sodium chloride, and the total nucleated
cells were counted with a hemocytometer using nigrosin
exclusion as a measure of viability. Leukocyte differentials
were determined in BAL fluid using cytocentrifuged (at
900rpm for 5min, Cytospin-4 Thermo Shandon,
Astmoor, Runcorn, Cheshire, England, UK) preparations
stained with May-Gru ¨ nwaldstain and Giemsa (Accustain,
Sigma, St Louis, MO, USA). Briefly the slides were allowed
to air dry for  10min, immersed in methanol, May-
Gru ¨ nwald and May Grunwald Buffer (pH 7.2, Sigma, St
Louis, MO, USA) for 5min each, and stained with Giemsa
for 15min. Stained BAL slide differentials were counted in
a blind manner by 3 individuals. The remaining cells were
analyzed phenotypically for T cell subpopulations using
specific antibodies and fluorescence flow cytometry. BAL
protein concentrations were measured in the supernatants
by bicinchoninic acid (BCA) protein assay using bovine
serum albumin as a standard (Pierce Biotechnology,
Rockford, IL, USA).
BAL-Cytokine Analysis
After collection of BAL, samples were centrifuged at
200g for 10min to remove cells. The BAL fluid
component was concentrated using an Amicon
Centriplus YM-10 filtration device (Millipore Corp.,
Bedford, MA, USA). Concentrated samples were then
analyzed for Th2 cytokines IL-5 and IL-13 using enzyme-
linked immunosorbent assay (ELISA) kits (Pierce
Biotechnology Rockford, IL; R&D Systems
Minneapolis, MN, USA) according to the manufacturer’s
directions. The limits of detection for IL-5 and IL-13
were 5 and 1.5pgml
 1, respectively.
BAL-Flow Cytometry and Immunofluorescence
BAL samples were prepared as previously described (23).
Briefly the samples were washed in PBS (Dulbecco’s
Phosphate Buffered Saline, pH 7.4, Sigma St Louis, MO,
USA) containing 0.2% bovine serum albumin and 0.1%
NaN3. Aliquots containing 10
4 to 10
5 cells were
incubated with 100ml of appropriately diluted antibodies
for 30min at 4 C. After staining, the cells were washed
twice with the above PBS solution, and relative fluores-
cence intensities were determined via flow cytometry
using a FACSCalibur and analyzed with BD
FACSDiva
TM Software v4.1 (Becton Dickinson,
San Jose, CA, USA). Eosinophils were gated on
forward and side scatter using a 4-decade log scale.
The following fluorescence labeled monoclonal antibodies
was used: CD19-PE (1D3), CD4-PerCP (RM4-5) and
CD8a-FITC (53-6.7) (Pharmingen, San Jose, CA, USA).
Histology
After sacrifice, non-inflated lungs from separate animals
were removed, fixed with 10% buffered formalin and
processed in a standard manner. Tissue sections were
stained with hematoxylin and eosin, Mallory’s trichrome
for collagen and periodic acid-schiff for mucus detection.
All specimens were evaluated with a microscope-mounted
Nikon Eclipse 400
TM camera (Tokyo, Japan). Digital
images were created using Spot RT Slider
TM Software
(Sterling Heights, MI, USA), and evaluated in Microsoft
Photo Editor
TM (Redmond, WA, USA).
Oral Bromelain administration
A stock solution of stem bromelain (EC 3.4.22.32), Lot #
1965 (Vital Nutrients, Middletown, CT, USA) was made
using 60mg of bromelain dissolved in 250ml of PBS.
Bromelain (200mgkg
 1) in 0.5ml of PBS was prepared
from the stock solution. Each animal received either
bromelain or saline via gavage using a 22gauge
 1inch
straight stainless steel feeding needle with a 1.25mm ball
tip (Braintree Scientific inc., Braintree, MA, USA), twice
a day. Bromelain or saline treatments were administered
6–8h apart, beginning 1day prior to aerosolization of
OVA. The dosages used were based on in vivo dose
response studies performed in our laboratory (23).
Bromelain was independently tested for authenticity,
potency (2400–2660GDUg
 1), microbial contamination,
residual solvents, heavy metals and aflatoxins
(Vital Nutrients, Middletown, CT; ChromaDex,
Clearwater, FL and Pharmline, Florida, NY, USA).
Ananas comosus (common pineapple) was identified by
the raw material provider (Indonesia) using organoleptic
techniques and bromelain identity was confirmed with
an Fourier transform infrared spectrometer (FTIR;
Pharmline, Florida, NY, USA).
Statistical Analysis
Statistical comparisons between groups were made with
analysis of variance and unpaired t-tests using StatView
4.5 (Abacus Concepts, Inc., Berkeley, CA, USA) and
JMP Software (SAS Institute Inc., Cary, NC, USA).
Dose-response data and cytokine levels were compared
by repeated measures analysis of variance. Changes in
Penh dose–response relationships were compared within
and between groups by repeated measures analysis of
variance. Changes in Penh-2 values before and after
aerosol exposure within groups were made by paired
t-tests and were compared between the control and
bromelain-treated groups by repeated measures analysis
of variance. All data were expressed as means standard
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significant at P 0.05.
Results
Treatment Protocol
Each animal received either bromelain (200mgkg
 1)i n
0.5ml of PBS or 0.5ml PBS alone via gavage (orally)
twice daily beginning 6 days after the third OVA–Alum
sensitization injection (Fig. 1). The treatments were
administered 6–8h apart, and all animals were sacrificed
 12h after the last treatment and the primary AAD
outcomes collected and assessed.
Analytical Testing and Quality Control
Bromelain was extracted from mature pineapple stems
with methanol and bound with  1% rice starch. Upon
importation, the certificate of analysis of bromelain was
independently verified for its purity ( 99%), identity (via
FTIR spectrometer) and potency (with a GDU assay)
(Table 1). Further analyses for quality and contamination
were performed for aflatoxins, heavy metals, chemical
solvents pesticides, herbicides and microbial contami-
nants. All samples were stored at 4 C in opaque
containers and source samples were stored for future
analysis of stability and degradation.
Decreased Pulmonary Eosinophilia Following Oral
Bromelain Administration
Total BAL eosinophils were significantly elevated in
AAD mice (167 33 10
4cells; P 0.0001) as compared
with naı¨ve (1 2 10
4cells) or naı¨ve oral bromelain-
treated (4 2 10
4cells) mice (Fig. 2A). There was a
significant reduction in total BAL eosinophils with
bromelain treatment of AAD mice as compared with
saline-treated AAD mice (P 0.02; Fig. 2A). Similar
trends were noted on evaluation of BAL samples with
flow cytometry (Fig. 2B). A representative FACS plot
showing gated eosinophils on forward and side scatter
from naı¨ve saline-treated (upper left), naı¨ve Bromelain-
treated (upper right), AAD saline-treated (lower left),
and AAD Bromelain-treated mice (lower right) are
shown.
Bromelain Modulates Lung Lymphocytes during Acute
Asthma
As compared with naı¨ve and naı¨ve bromelain-treated
mice, AAD mice displayed significant increases in the
percentage of BAL CD4þ, CD8þ and CD19þ lympho-
cytes (Fig. 3). Bromelain-treated AAD mice resulted in
significant reductions in CD8þ (19 1 versus 9 2;
P 0.002), and CD19þ lymphocytes (2.4 0.3 versus
2.4 0.2; P 0.002) when compared with AAD-saline-
treated mice. No significant changes in CD4þ lympho-
cytes were noted in similar comparisons.
Reduced IL-13 Levels in the BAL of Bromelain-treated
Mice
A significant decrease in IL-13 concentration was
observed in bromelain-treated AAD mice as compared
with the saline treated AAD mice (41 12 versus
86 18pg/ml; Fig. 4). There were no significant changes
in BAL IL-5 concentrations with oral bromelain treat-
ment of AAD mice as compared with saline treated AAD
mice (20 4 versus 24 2pg/ml).
Shifts in Airway Responsiveness Following Bromelain
Treatment
Airway responses to methacholine were assessed by
whole-body barometric plethysmography using the
Buxco system (Sharon, CT, USA). At baseline, before
bromelain or saline treatment (open circles), both
groups of animals had similar overall responsiveness
(Fig. 5A; P¼0.50) and sensitivity (Fig. 5B) to methacho-
line (Penh-2 values 48 13mg/ml in the bromelain
treatment versus 64þ15mg/ml in saline treatment
group; P¼0.47). At AAD (filled circles), saline-treated
mice tended to be more generally responsive to metha-
choline (P¼0.069; A) and were twice as sensitive to
methacholine (P¼0.01; B). No change occurred in
bromelain-treated 3-day OVA mice terms of overall
responsiveness (P¼0.52; A) or methacholine sensitivity
(P¼0.45; B).
Figure 1. Bromelain treatment protocol. Each animal was sensitized
with 3 OVA-Alum i.p. injections 1 week apart ( 21 days,  14 days,
 7 days). Six days after the third injection ( 1 day) each animal
received either Bromelain (200mg/kg) in 0.5ml of phosphate buffered
saline (PBS) or 0.5ml PBS alone via gavage (orally). Treatment was
administred twice daily (6–8h apart) for 4 consecutive days. Animals
were challenged with 1% OVA in saline for 1h per day (0–3). All
animals were sacrificed 12h after the last treatment (day 3) and the
primary AAD outcomes assessed.
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Pathology
Histological evaluations and Pathology Scores (PS), were
performed on unmanipulated, uninflated formalin-fixed
lungs from separate groups (n¼4) of naı¨ve, naı¨ve
bromelain-treated, AAD saline- and AAD bromelain-
treated mice stained with hematoxylin and eosin (H & E),
Mallory’s trichrome and periodic acid-schiff. The H & E
stain has been included for comparison (Fig. 6).
As demonstrated in the top panels, no evidence of
histological injury was noted in naı¨ve animals (A) or oral
bromelain-treated naı¨ve animals (B). Three day AAD
mice develop mild pathologic changes, characterized by
perivascular and peribronchial (arrows) inflammation
which includes cellular infiltrates (lymphocytes, plasma
cells and eosinophils). These changes are present in
the 3-day AAD saline-treated mice (C). Oral bromelain-
treated AAD mice (D) appeared to have minimal
histological injury. However, upon statistical comparisons
of pathological scoring by four reviewers, there were
no statistical changes in pathological scoring.
Discussion
The current study is a continued characterization of the
use of bromelain, a cysteine protease extracted from
Table 1. Bromelain Identity and Quality Control Data
Bromelain quality control and analytical testing data
Item/test profile Specification Result Method
Botanical—Pineapple Ananas cosmosus Ananas cosmosus Visual
Plant parts used Mature stem Mature stem Visual
Botanical extract Bromelain (EC 3.4.22.31) Bromelain (EC 3.4.22.31) Methanol extraction
Identification Standard match (Sigma) Conforms to standard FTIR, HPLC
Activity, potency  2400GDU/g 2674GDU/g GDU assay
Solvent residues
Methanol  3000ppm Negative Gas chromatography
Ethanol  5000ppm Negative Gas chromatography
Acetone  5000ppm Negative Gas chromatography
Isopropanol  5000ppm Negative Gas chromatography
Methylene chloride  600ppm Negative Gas chromatography
Hexane  290ppm Negative Gas chromatography
Ethyl acetate  5000ppm Negative Gas chromatography
Microbial profile Total plate count  3000/g  50/g
Mold  300/g  50/g STVCA
E. Coli Negative Negative STVCA
Salmonella Negative Negative STVCA
Coliforms  10/g Negative USP24p. 1814
S. aureus Negative Negative USP24p. 1814
P. aeruginosa Negative Negative USP24p. 1814
Aflatoxin profile (G2, G1, B2, B1) Aflatoxins  20ppb  1ppb HPLC
Heavy metal profile
Aluminum  1000ppm 16 0.5ppm ICP–MS
Arsenic  3ppm  0.50 0.5ppm ICP–MS
Lead  10ppm 0.07 0.05ppm ICP–MS
Cadmium  3ppm  0.25þ0.25ppm ICP–MS
Mercury  2ppm  0.10þ0.1ppm ICP–MS
Pesticide residues CDFA
Organochlorines  5ppm Negative Gas and liquid
Organophosphates  7ppm Negative chromatography
Organonitrates  5ppm Negative coupled with mass
Carbamates  5ppm Negative spectrometry
EC¼enzyme classification; FTIR¼Fourier transform infrared spectroscopy; HPLC¼high-performance liquid chromatography; GDUs¼gelatin
dissolving units; STVCA¼Soleris’ total viable count assay; ICP–MS¼inductively coupled plasma – mass spectrometry; CDFA¼California
Department of Food and Agriculture.
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i.p. administration of bromelain exerts anti-inflammatory
effects in an OVA-induced murine model of AAD (23).
The present study was designed to determine the efficacy
of oral bromelain treatment in a murine model of
asthma. The data presented in this study demonstrate
that oral bromelain therapy can attenuate inflammation
in a well-characterized murine model of asthma (23–25)
Figure 2. The effect of oral Bromelain treatment on BAL eosinophils. Total BAL eosinophils were significantly elevated in AAD mice as compared
to naı¨ve or naı¨ve oral Bromelain-treated mice (P 0.0001; A). There was a significant reduction in total BAL eosinophils with Bromelain treatment
of AAD mice as compared to saline treated AAD mice. Similar trends were noted on evaluation of BAL samples with Flow cytometry (B).
A representative FACS plot showing gated eosinophils on forward and side scatter from; naı¨ve-saline treated (upper left), naı¨ve-Bromelain treated
(upper right), AAD-saline treated mice (lower left), and AAD-Bromelain treated mice (lower right) are shown. Statistical comparisons were made by
un-paired t-test, *P 0.02; Data represent means SEM, n¼8 animals per group.
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bioavailable and efficacious for the treatment of inflam-
matory conditions (14,26–30).
The quality control and analytical verification
of botanical products such as bromelain remain a
concern as the use of these products continues to
increase (6,31–33). Many botanicals are now undergoing
intensive testing to ensure safety and quality for
consumers and reproducibility for basic science and
clinical research (34–36). The bromelain utilized for
these experiments was obtained from a professional
natural product manufacturing company that produces
products for clinical use. The bromelain extract was
independently evaluated for purity, potency and contam-
ination to ensure quality and reproducibility (Table 1).
There were no solvent residues, microbial contamination,
or greater than acceptable heavy metals or pesticide
residues. There was no observed toxicity of oral
bromelain treatment in either naive or AAD animals
Figure 3. The effect of oral Bromelain treatment on BAL Lymphocytes.
After 3 OVA aerosol exposures, there was a significant increase in the
percentages of CD19þB cells (A) CD8þ T cells (B) and CD4þ T cells
(C) in the BAL of AAD mice, as compared to naı¨ve controls.
Oral Bromelain treatment significantly reduced CD19þ B cells
(P 0.00003; A), and CD8þ T cells (P 0.00002; B). There was no
change in the percentages of CD4þT cells in the BAL between AAD
and Bromelain treated AAD mice (P 0.095; C). Statistical compar-
isons were made by un-paired t-test, *P 0.0001; Data represent
meansþSEM, n¼8 animals per group.
Figure 4. The effect of oral Bromelain treatment on IL-5 and IL-13
concentrations in BAL. There were no significant changes in BAL IL-5
concentrations with oral Bromelain treatment of AAD mice as
compared to saline treated AAD mice. A significant decrease in IL-13
concentration was observed in oral Bromealin treated AAD mice as
compared to the saline treated AAD mice. Statistical comparisons were
made by un-paired t-test, *P 0.04; Data represent means SEM, n¼8
animals per group.
A
B
Figure 5. The effect of oral Bromelain treatment on airway reactivity
and methacholine sensitivity. At baseline (open circles), Bromelain-
treated and saline-treated mice had similar reactivity (P¼0.50) and
sensitivity to methacholine (p2 values 48 13 mg/ml in Bromelain
treated versus 64 15 mg/ml in saline treated; P¼0.47). After 3 OVA
aerosol exposures (filled circles), saline treated mice tended to be more
reactive to methacholine (P¼0.069; A) and were twice as sensitive to
methacholine (P¼0.01; B) whereas no change occurred in Bromelain
treated mice in reactivity (P¼0.52; A) and sensitivity (P¼0.45; B).
Comparisons were made by paired t-test and repeated measures
ANOVA; n¼7–8 animals per group.
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and lung pathology).
The presence of increased BAL eosinophils is a
hallmark of asthma. Compared with saline-treated
AAD mice, bromelain-treated AAD mice had signifi-
cantly reduced lung eosinophilia as observed by BAL
differential and flow cytometry (Fig. 2). This observed
effect of bromelain treatment on eosinophils may be due
to a reduction in lymphocyte populations or a decrease in
the Th2 cytokines that are responsible for the recruitment
of eosinophils into the lung during asthma. Therefore, we
examined the effect of oral bromelain treatment on Th2
cytokines (IL-5, IL-13) and lymphocyte subsets (CD4þ,
CD8þ and CD19þ). Bromelain treatment reduced the
percentages of CD8þ T cells and CD19þ B cells in the
BAL (Fig. 3) and BAL IL-13 concentrations (Fig. 4).
CD19þ B cells can act as primary antigen presenting cells
in Th2 conditions such as asthma. A bromelain-mediated
reduction in this subset may also diminish T cell driven
inflammation thereby inhibiting the progression of
allergic disease. Though, primarily a CD4þ T cell
mediated condition, CD8þ T cells which secrete Th2
cytokines, have also been implicated in asthma (37).
A reduction in these CD8þ T cells via bromelain may
have additional protective effects by modulating lympho-
cyte-mediated cytotoxic asthma mechanisms such as
granzymes or perforins. The effects of bromelain on the
lymphocyte subpopulations were observed locally as
represented by the BAL and not systemically
(in peripheral blood or spleen, data not shown) suggest-
ing that bromelain activity is focused at sites of
inflammation.
Interestingly, the percentages of CD4þ T cells were not
significantly reduced. This may be due to bromelain
altering the ratio of CD4þ T cell subsets, mainly the
effector cells (CD4þCD25 Foxp3 ) which cause airway
inflammation, to regulatory cells (CD4þCD25þ
Foxp3þ) which suppress it. Bromelain may enhance
regulatory cell numbers and their function leading to the
resolution of disease. The characterization of the effects
of bromelain on these regulatory T cells is currently being
investigated in our laboratory.
In addition, we examined the effects of bromelain
treatment in asthma on both pulmonary function (PFT)
and pathology. As a measure of pulmonary function,
both saline and bromelain treatment groups were
challenged to increasing doses (0–300mg/ml) of metha-
choline, a common lung smooth muscle irritant, for
assessment of airway reactivity and sensitivity (Fig. 5).
During the baseline challenge, there was no difference
between the groups. After OVA aerosols, the saline-
treated group became more sensitive to methacholine
whereas the bromelain group did not vary from baseline.
This protective effect on lung function correlates well
with the observed reductions in eosinophils, lymphocytes
and cytokines that have been implicated in the pathogen-
esis of airway reactivity (38–41). In regards to lung
pathology (Fig. 6), bromelain-treated mice appeared to
qualitatively have reduced pulmonary injury as compared
with saline-treated controls; however, independent
blinded scoring did not reveal significant differences
between the groups.
Future studies will evaluate the effects of bromelain in
a 7–10day AAD model with more advanced disease and
bromelain administration will be varied after the onset of
asthma (3 days of aerosol) to better simulate a clinical
presentation and given during or before OVA sensitiza-
tion to evaluate its effect on the priming response.
Experiments are currently being designed to evaluate the
effect of bromelain treatment on key immunoregulatory
CD4þ T cell subsets such as Foxp3þ T regulatory cells
which are known to modulate allergic responses (42,43)
and to measure the retained enzymatic activity of
bromelain in the serum of naı¨ve and AAD mice after
oral administration. In conclusion, the results obtained
from this study suggest that the oral administration of
bromelain attenuates inflammation in an OVA-induced
murine model of asthma. These results may translate well
in clinical trials.
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Figure 6. The effect of oral Bromelain treatment on lung pathology.
Top panels: No evidence of histological injury was noted in naı¨ve
animals (A) or oral Bromelain treated naı¨ve animals (B). Lower panels:
As previously described, 3 day AAD mice develop pathological changes
characterized by perivascular and peribronchiolar infiltration of
lymphocytes, eosinophils and plasma cells (C), which was reduced in
oral Bromelain treated AAD mice (D).
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